Zhao Liu1, J Emanuel Finet2, Julie A Wolfram1, Mark E Anderson3, Xun Ai4, J Kevin Donahue5. 1. Division of Cardiology, University of Massachusetts Medical School, Worcester, Massachusetts. 2. Division of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio. 3. Department of Medicine, Johns Hopkins University Medical School, Baltimore, Maryland. 4. Department of Physiology & Biophysics, Rush University Medical School, Chicago, Illinois. 5. Division of Cardiology, University of Massachusetts Medical School, Worcester, Massachusetts. Electronic address: donahuelab@gmail.com.
Abstract
BACKGROUND: Atrial fibrillation (AF) is sustained by reentrant mechanisms that depend, in part, on atrial structural remodeling. Increased Ca2+/calmodulin-dependent protein kinase II (CaMKII) activity occurs in persistent AF. A general consensus has been that electrophysiological actions of CaMKII must be the contributing factor, but electrical remodeling in AF differs considerably with electrophysiological effects of CaMKII. CaMKII has been associated with structural remodeling in several tissues, but not the cardiac atria. The role of CaMKII in sustaining AF remains undefined. OBJECTIVE: The purpose of this study was to assess the effects of CaMKII on AF-related structural remodeling. METHODS: We evaluated the objective in a porcine AF-heart failure model using atrial gene transfer of the CaMKII inhibitory peptide CaMKIIn. We used conventional methods including in vivo electrophysiological study, telemetry, western blot, echocardiography, and histology to quantify rhythm, function, microstructure, and signaling pathways relevant to CaMKII and structural remodeling. RESULTS: CaMKII levels and activity increased progressively in the early stages of AF-heart failure. Inhibiting CaMKII preserved atrial contractile function and attenuated atrial hypertrophy, fibrosis, and apoptosis but did not affect inflammation or myolysis. These effects were accompanied by significantly decreased phosphorylation of HDAC4, decreased expression of p38MAP-kinase, and alterations in the phosphorylation pattern and relative ratios of JNK isoforms. CONCLUSION: Our findings suggest that CaMKII mediates signaling pathways related to atrial contractile function and structural remodeling in AF. CaMKII inhibition is potentially a novel therapy for AF. These findings are of importance because no clinically relevant mediators of either atrial contractile function or structural remodeling have yet been identified.
BACKGROUND: Atrial fibrillation (AF) is sustained by reentrant mechanisms that depend, in part, on atrial structural remodeling. Increased Ca2+/calmodulin-dependent protein kinase II (CaMKII) activity occurs in persistent AF. A general consensus has been that electrophysiological actions of CaMKII must be the contributing factor, but electrical remodeling in AF differs considerably with electrophysiological effects of CaMKII. CaMKII has been associated with structural remodeling in several tissues, but not the cardiac atria. The role of CaMKII in sustaining AF remains undefined. OBJECTIVE: The purpose of this study was to assess the effects of CaMKII on AF-related structural remodeling. METHODS: We evaluated the objective in a porcine AF-heart failure model using atrial gene transfer of the CaMKII inhibitory peptide CaMKIIn. We used conventional methods including in vivo electrophysiological study, telemetry, western blot, echocardiography, and histology to quantify rhythm, function, microstructure, and signaling pathways relevant to CaMKII and structural remodeling. RESULTS: CaMKII levels and activity increased progressively in the early stages of AF-heart failure. Inhibiting CaMKII preserved atrial contractile function and attenuated atrial hypertrophy, fibrosis, and apoptosis but did not affect inflammation or myolysis. These effects were accompanied by significantly decreased phosphorylation of HDAC4, decreased expression of p38MAP-kinase, and alterations in the phosphorylation pattern and relative ratios of JNK isoforms. CONCLUSION: Our findings suggest that CaMKII mediates signaling pathways related to atrial contractile function and structural remodeling in AF. CaMKII inhibition is potentially a novel therapy for AF. These findings are of importance because no clinically relevant mediators of either atrial contractile function or structural remodeling have yet been identified.
Authors: J Mühlhauser; M Jones; I Yamada; C Cirielli; P Lemarchand; T R Gloe; B Bewig; S Signoretti; R G Crystal; M C Capogrossi Journal: Gene Ther Date: 1996-02 Impact factor: 5.250
Authors: Michael M Kreusser; Lorenz H Lehmann; Stanislav Keranov; Marc-Oscar Hoting; Ulrike Oehl; Michael Kohlhaas; Jan-Christian Reil; Kay Neumann; Michael D Schneider; Joseph A Hill; Dobromir Dobrev; Christoph Maack; Lars S Maier; Hermann-Josef Gröne; Hugo A Katus; Eric N Olson; Johannes Backs Journal: Circulation Date: 2014-08-14 Impact factor: 29.690
Authors: Rong Zhang; Michelle S C Khoo; Yuejin Wu; Yingbo Yang; Chad E Grueter; Gemin Ni; Edward E Price; William Thiel; Silvia Guatimosim; Long-Sheng Song; Ernest C Madu; Anisha N Shah; Tatiana A Vishnivetskaya; James B Atkinson; Vsevolod V Gurevich; Guy Salama; W J Lederer; Roger J Colbran; Mark E Anderson Journal: Nat Med Date: 2005-03-27 Impact factor: 53.440
Authors: Jenelle M Timmins; Lale Ozcan; Tracie A Seimon; Gang Li; Cristina Malagelada; Johannes Backs; Thea Backs; Rhonda Bassel-Duby; Eric N Olson; Mark E Anderson; Ira Tabas Journal: J Clin Invest Date: 2009-09-08 Impact factor: 14.808
Authors: Niels Voigt; Na Li; Qiongling Wang; Wei Wang; Andrew W Trafford; Issam Abu-Taha; Qiang Sun; Thomas Wieland; Ursula Ravens; Stanley Nattel; Xander H T Wehrens; Dobromir Dobrev Journal: Circulation Date: 2012-03-28 Impact factor: 29.690